Literature DB >> 8174792

Review of accidents caused by incomplete inactivation of viruses.

F Brown1.   

Abstract

Inactivation of viruses and bacterial toxins with formaldehyde for the preparation of vaccines has been a favourite method for most of this century. The Cutter incident in 1955 with poliovaccine focussed attention on the problems accompanying the procedure for inactivating viruses although it had been known since the 1930s that the method was not without its dangers. It had also been known since about the same time that foot-and-mouth disease vaccines prepared in this way could carry residual infectivity. The molecular methods of analysis introduced in the 1970s proved without any doubt that the outbreaks in France in 1981 and in other countries of Western Europe in the 1980s were caused by improperly inactivated vaccines. Recent molecular evidence has now shown that formaldehyde-inactivated Venezuelan equine encephalitis vaccines were the probable cause of the outbreaks of the disease during the 1969-1972 pandemic in Central America. In the author's opinion it is remarkable that formaldehyde is still used for the preparation of inactivated vaccines, particularly since it is known that the procedure also affects the immunogenic epitopes of the viruses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8174792

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  26 in total

Review 1.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

2.  Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.

Authors:  Kanakatte Raviprakash; Peifang Sun; Yossef Raviv; Thomas Luke; Nicholas Martin; Tadeusz Kochel
Journal:  Hum Vaccin Immunother       Date:  2013-07-08       Impact factor: 3.452

3.  Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.

Authors:  J L Rossio; M T Esser; K Suryanarayana; D K Schneider; J W Bess; G M Vasquez; T A Wiltrout; E Chertova; M K Grimes; Q Sattentau; L O Arthur; L E Henderson; J D Lifson
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  Effects of UVA irradiation, aryl azides, and reactive oxygen species on the orthogonal inactivation of the human immunodeficiency virus (HIV-1).

Authors:  Julie M Belanger; Yossef Raviv; Mathias Viard; M Jason de la Cruz; Kunio Nagashima; Robert Blumenthal
Journal:  Virology       Date:  2011-07-02       Impact factor: 3.616

5.  Characterization of CD8+ T cell function and immunodominance generated with an H2O2-inactivated whole-virus vaccine.

Authors:  Joshua M Walker; Hans-Peter Raué; Mark K Slifka
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

6.  Development of a new hydrogen peroxide–based vaccine platform.

Authors:  Ian J Amanna; Hans-Peter Raué; Mark K Slifka
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

7.  Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice.

Authors:  Ryan C Maves; Roger M Castillo Oré; Kevin R Porter; Tadeusz J Kochel
Journal:  Clin Vaccine Immunol       Date:  2009-12-09

8.  Eastern equine encephalomyelitis virus infection in a horse from California.

Authors:  Robert P Franklin; Hailu Kinde; Michele T Jay; Laura D Kramer; Emily-Gene N Green; Robert E Chiles; Eileen Ostlund; Stan Husted; Jonathan Smith; Michael D Parker
Journal:  Emerg Infect Dis       Date:  2002-03       Impact factor: 6.883

Review 9.  Vaccine adjuvants: current challenges and future approaches.

Authors:  Jennifer H Wilson-Welder; Maria P Torres; Matt J Kipper; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

Review 10.  Wanted, dead or alive: new viral vaccines.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Antiviral Res       Date:  2009-09-04       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.